January 25 - 29, 2025
San Diego, CA, USA
Register today to explore a comprehensive portfolio of technologies that span more steps in the drug discovery process than ever before—ranging from molecular identity characterization and high-throughput hit screening to dynamic interaction profiling and cellular assays.
Unlock new possibilities in single B-cell screening for biologics discovery, harness high-throughput mass spectrometry and Surface Plasmon Resonance for lead identification and development, and achieve groundbreaking insights into molecular interactions with single-cell Interaction Cytometry, enabling kinetic measurements directly on cells.
Accelerate your research with the innovative tools trusted by leading scientists and pharmaceutical innovators around the globe.
Location: Room 24C
Lab automation technologies are transforming biologics development by streamlining the selection and optimization of candidates. However, the complexity of biologics—often involving intricate structures and binding interactions—presents challenges in optimizing pharmacokinetics, efficacy, and safety.
This presentation highlights three advanced automated biophysical tools: high-throughput, multiplexing Surface Plasmon Resonance (SPR) for rapid candidate identification and detailed lead development, switchSENSE® for analyzing avidity effects and multispecific binders, and single-cell Interaction Cytometry for real-time kinetic measurements directly on cells to assess native binding properties.
These tools offer comprehensive profiling to accelerate biologics development by identifying lead candidates with optimal biophysical characteristics and are also applicable to other therapeutic modalities like small molecules.
Prof. Ulrich Rant, Ph.D., CSO Bruker Biosensors, Munich, Germany
Cyrill Brunner, Ph.D., Senior Application Scientist, Bruker Switzerland, Fällanden, Switzerland
Location: Location: Room 24C
Bruker Cellular Analysis presents innovative solutions for camelid heavy chain-only antibody (HCAb) discovery, specifically for challenging targets, using the Beacon® Optofluidic Platform.
The Beacon® Platform enables rapid, specific antibody identification and offers modular kits that integrate seamlessly with immunization workflows, supporting each stage from initial immunization to final antibody selection. By reducing development time and enhancing discovery success, this end-to-end approach optimizes antibody campaigns.
The session will showcase how Beacon’s microfluidic technology isolates and analyzes single B cells, allowing researchers to efficiently identify rare, high-quality therapeutic antibodies.
Vincent Pai, Director of Product Management at Bruker Cellular Analysis, Emeryville, CA, United States
As you are certainly aware, special compliance regulations apply to public officials* and healthcare professionals** with regard to the event we are planning. If you accept our invitation, we will therefore assume that you will observe the compliance regulations that apply to you and that you have the necessary employer approval.
*Government Official means according the Bruker policies any of the following: any officer, employee or representative of a government (national, regional or local) entity, or any public agency, public authority, department or instrumentality thereof, regardless of their rank or title (e.g. a regulatory official or government inspector); any person working for or advising a government-owned or government-controlled enterprise (e.g. a professor at a government-owned university, or a purchaser at a government-owned hospital); any person working for or advising a national or international non-governmental organization (e.g. an employee of the Red Cross or The World Bank); any person performing a public function or providing a public service, even if that person works for a non-governmental institution (e.g. private security personnel working in public functions); any person hired to review or accept bids for a government agency; any person with the responsibility to allocate or expend government funds; any person in a public law function, civil servant, judge or military personnel; any person acting for a political party, including party officials, candidates or individuals holding a position in a political party office; members of royal families; or immediate family members of any of the persons listed above. An immediate family member is a grandparent, parent, spouse, significant other, child, or sibling.
**A Healthcare Professional (HCP) is in accordance with the Bruker policies any physician, dentist, nurse, pharmacist or other individual who may prescribe, administer, purchase, dispense, recommend, or supply medical products or treatments or pharmaceutical products. In many cases, Bruker interacts with HCPs who work for state-owned hospitals (e.g. as medical scientists). These individuals will be classified as both HCPs and Government Officials.
For Research Use Only. Not for use in clinical diagnostic procedures.